Ionis Cuts Tryngolza 2026 Sales Guide to $50M, Q3 Revenue Jumps 55%

Ionis Pharmaceuticals (Nasdaq: IONS) reported third quarter 2026 revenue of $243 million and a GAAP operating loss of $130 million on November 9, 2026, while cutting full-year Tryngolza (olezarsen) product sales guidance to roughly $50 million from a prior $100-110 million range. The company reaffirmed total revenue guidance of $875-900 million, Dawnzera guidance of $110-120 million, non-GAAP operating loss of $425-475 million and cash above $1.6 billion. Tryngolza generated $9 million in U.S. net product sales in the quarter.

Context — why the Tryngolza reset matters now

Ionis framed the cut around launch mechanics rather than demand collapse. The company said the severe hypertriglyceridemia market requires establishing "a new treatment paradigm," and that the ramp is tracking more gradually than its own earlier model assumed. That is a company explanation for a company forecast.

The prior guidance of $100-110 million was issued alongside the same total revenue range the company still holds. Ionis reaffirmed everything except Tryngolza, which tells investors the miss is product-specific rather than a company-wide shortfall.

The comparison that matters sits in the revenue table. Tryngolza U.S. net sales were $32 million in the third quarter of 2025 and $57 million across the first nine months of 2025, when the drug was sold only in familial chylomicronemia syndrome. Adding a far larger sHTG indication has so far produced lower quarterly sales than the narrow label did a year ago.

Dawnzera is doing the opposite. U.S. net sales reached $37 million in the quarter and $79 million over nine months, against $1 million in each prior-year period. The hereditary angioedema launch is now the revenue engine the company expected Tryngolza to become.

Macro conditions are not the stated driver. The report attributes the ramp entirely to prescriber behavior and payer dynamics in a newly created category, not to financing costs or sector-wide biotech risk appetite.

Data — what the numbers show

Total revenue rose 55% year over year in the quarter, to $243 million from $157 million, and 64% over nine months excluding the one-time $280 million sapablursen upfront payment Ionis received from Ono Pharmaceutical in the second quarter of 2025. That payment inflates the prior nine-month base, which is why the company strips it out.

Metric	Q3 2026	Q3 2025
Total revenue	$243M	$157M
Product sales, net	$48M	$33M
Royalty revenue	$81M	$76M
Operating expenses	$373M	$317M
Loss from operations	$130M	$160M

The operating loss narrowed on a GAAP basis despite expenses climbing 18%, because revenue grew faster. On a non-GAAP basis the quarterly loss was $87 million versus $129 million a year earlier. Across nine months, though, the GAAP loss widened to $350 million from $167 million.

Cash, cash equivalents and short-term investments fell to $1.9 billion from $2.7 billion at December 31, 2025. Ionis attributed the decline to repaying its 0% convertible notes on April 1, 2026 and to funding operations.

Partnered royalties carried the quarter. Spinraza global sales of $461 million produced $69 million in royalties, up 23% year over year. Wainua global sales of $68 million produced $7 million in royalties, down from $13 million a year earlier. Collaborative agreement revenue jumped to $103 million from $31 million.

Analysis — what it means for markets and sectors

The guidance cut is narrow but the read-through is broad. Tryngolza was positioned as the first large-indication launch for Ionis, and its pace now determines whether the company reaches sustained positive cash flow on the timeline management has described.

Exposure runs across the RNA and cardiometabolic complex. Ionis collects royalties on Spinraza from Biogen, on Wainua from the AstraZeneca group, on Hibsago from the GSK group, and it commercializes Zanvastro outside the U.S. with Recordati assuming approval. A slower Tryngolza ramp pressures Ionis directly without changing those partners' economics.

The counter-argument deserves weight. Ionis reaffirmed total revenue, operating loss and cash guidance, and it has three approved first-in-class medicines in 2026, two of them wholly owned. Pipeline news has been positive: sefaxersen met its Phase 3 primary endpoint in IgA nephropathy with a 43.1% proteinuria reduction versus placebo at week 37, and ulefnersen met its primary endpoint in FUS ALS with p=0.0005.

One limitation is that the company did not disclose prescription volumes, payer coverage rates or gross-to-net dynamics behind the slower ramp. Without those, investors cannot distinguish a timing problem from a demand problem, and the reaffirmed total revenue guidance partly depends on collaborative revenue rather than product sales.

Positioning reflects that uncertainty. Product-sales guidance carries more weight than pipeline readouts for near-term holders, and a stock priced on a multi-billion-dollar peak sales claim now has to defend a $50 million first year.

Outlook — what to watch next

Three catalysts sit on the calendar the report gives. A final European approval decision for Tryngolza in sHTG is expected in the fourth quarter of 2026, following a positive CHMP opinion. Data from the Phase 3 REVEAL study of obudanersen in Angelman syndrome is expected in the second half of 2027. And management will host its earnings call at 9:00 a.m. Eastern on November 9, 2026.

For Dawnzera, the test is whether the $79 million nine-month run rate holds into the fourth quarter to reach the reaffirmed $110-120 million full-year band. Any shortfall there would remove the offset that currently cushions the Tryngolza reset.

Cash is the constraint to monitor. With $1.9 billion on the balance sheet against a reaffirmed floor above $1.6 billion, the company has roughly $300 million of headroom against its own stated minimum, and fourth-quarter spending on three simultaneous launches will draw against it.

Frequently Asked Questions

Why did Ionis cut its Tryngolza guidance?

Ionis said the sHTG launch is ramping more gradually than it anticipated as it establishes a new treatment paradigm, and that it has identified opportunities to improve performance. The company lowered full-year Tryngolza product sales guidance to approximately $50 million from $100-110 million while reaffirming total revenue, operating loss and cash guidance. It did not disclose prescription volumes or coverage data behind the change.

What does the Tryngolza cut mean for retail investors in Ionis?

It shifts the near-term story from a large-indication launch to the rest of the portfolio. Dawnzera product sales guidance of $110-120 million is unchanged, royalty income from Spinraza and Wainua is intact, and partnered pipeline assets advanced with sefaxersen and ulefnersen Phase 3 wins. The company still expects a non-GAAP operating loss of $425-475 million for the year.

How does Dawnzera compare with Tryngolza as a launch?

Dawnzera reached $37 million in third-quarter U.S. net sales and $79 million over nine months, against $1 million in each comparable 2025 period, and is on track for $110-120 million for the year. Tryngolza generated $9 million in the quarter and $41 million over nine months. Both are wholly owned, so the mix between them drives Ionis commercial revenue directly.

Bottom Line

Ionis kept its full-year revenue and cash targets but halved Tryngolza's first-year sales expectation, putting the launch burden on Dawnzera.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.